Ambeed.cn

首页 / / / / Lopinavir

洛匹那韦 /Lopinavir {[allProObj[0].p_purity_real_show]}

货号:A330804 同义名: ABT-378;A-157378.0

Lopinavir(ABT-378)是一种高效选择性的HIV-1蛋白酶抑制剂,对野生型和突变型HIV蛋白的Ki值在1.3至3.6 pM之间。其作用是阻止HIV-1的成熟,从而阻止其感染性。Lopinavir还表现出对SARS-CoV 3CLpro的抑制作用,IC50为14.2 μM。

Lopinavir 化学结构 CAS号:192725-17-0
Lopinavir 化学结构
CAS号:192725-17-0
Lopinavir 3D分子结构
CAS号:192725-17-0
Lopinavir 化学结构 CAS号:192725-17-0
Lopinavir 3D分子结构 CAS号:192725-17-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Lopinavir 纯度/质量文件 产品仅供科研

货号:A330804 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 HIV Protease HIV-1 caspid 其他靶点 纯度
Dextran sulfate sodium, mw 40,000 M.W 40000
Vicriviroc maleate 98+%
Rosamultin 97%
Darunavir 98%
Lopinavir ++++

HIV protease, Ki: 1.3 pM

99+%
Chloroquine Autophagy 95%
Amprenavir +

HIV protease, IC50: 14.6 ng/mL

PXR 99%+
NBD-556 99%+
Nelfinavir Mesylate +++

HIV protease, Ki: 2 nM

99%+
Atazanavir Sulfate 98%
Limonin 98%
Saquinavir ++

HIV proteinase, IC50: 2.7 nM

98%
Ritonavir 98%
Azvudine 98%
Lenacapavir ++++

HIV-1 capsid, EC50: 0.1 nM

97%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Lopinavir 生物活性

靶点
  • HIV Protease

    HIV protease, Ki:1.3 pM

描述 Lopinavir (ABT-378) is an antiretroviral of the HIV protease inhibitor class, as well as an inhibitor of P-Glycoprotein, Cytochrome P450 3A and Organic Anion Transporting Polypeptide 1B1. It has a mean oral bioavailability of less than 20 % due to extensive hepatic metabolism by cytochrome P450 3A4. The reported half-life of Lopinavir is 5-6 hours and the maximum recommended daily dose is 400 mg/day[3]. In a randomised controlled trial done in HIV-infected adults or adolescents, at 144 weeks, 86% participants in the protease inhibitor plus nucleoside reverse-transcriptase inhibitor (NRTI) group (lopinavir 400 mg with ritonavir 100 mg, twice per day plus two or three clinician-selected NRTIs) had viral loads of less than 400 copies per mL compared with 81% in the protease inhibitor plus raltegravir (400 mg twice per day) group[4]. Promastigotes of L. amazonensis (the cause of tropical disease Leishmaniasis) treated with increasing concentrations of lopinavir (7.5, 15 and 30 µM) exhibited accumulation of lipid inclusions and increased amounts of cholesterol-ester in a dose-dependent manner, which reinforced that lopinavir can be useful in leishmaniasis treatment[5]. In Human Glioblastoma U-87 MG cell line, co-treatment with Lopinavir and Ritonavir (25 and 50 µM) for 24 h promoted a significant increase in ROS production, caused mitochondrial network damage and induced apoptosis in a caspase-independent manner[6]. In the latest study, Lopinavir was found to have anti-2019-novel coronavirus activity.

Lopinavir 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
HEK293 cells Function assay 48 h Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay, EC50=0.0028 μM 17638694
human MT4 cells Function assay 5 days Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay, EC50=0.006 μM 17576848
human PBMC cells Function assay 5 days Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay, EC50=0.015 μM 17576848
MT2 cells Function assay Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay, EC50=0.0026 μM 17371811

Lopinavir 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00661349 HIV Infections Phase 4 Terminated(It has been impossi... 展开 >>ble to achieve the number of patients defined by protocol) 收起 << - Spain ... 展开 >> Hospital Son Dureta Palma de Mallorca, Baleares, Spain, 07014 H.U. Germans Trias i Pujol - Unitat VIH, Fundació Lluita contra la Sida Badalona, Barcelona, Spain, 08916 Hospital General Universitario de Alicante Alicante, Spain, 03010 Hospital Clínic i Provincial de Barcelona Barcelona, Spain, 08036 Hospital Universitario Príncipe de Asturias Madrid, Spain, 28005 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital Universitario la Paz Madrid, Spain, 28046 Hospital Clínico de Salamanca Salamanca, Spain, 37007 Hospital Universitario de Valme Sevilla, Spain, 41014 收起 <<
NCT00262522 Human Immunodeficiency Virus I... 展开 >>nfections 收起 << Phase 3 Completed - -
NCT00105079 HIV Infections Phase 3 Completed - -

Lopinavir 参考文献

[1]Vishnuvardhan D, Moltke LL, et al. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4.

[2]Sham HL, Kempf DJ, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24.

[3]Ansari H, Singh P. Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV. Curr HIV Res. 2018;16(4):270-279. doi: 10.2174/1570162X16666180924101650. PMID: 30246641; PMCID: PMC6416462.

[4]Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3. PMID: 29108797; PMCID: PMC5739875.

[5]Rebello KM, Andrade-Neto VV, Zuma AA, Motta MCM, Gomes CRB, de Souza MVN, Atella GC, Branquinha MH, Santos ALS, Torres-Santos EC, d'Avila-Levy CM. Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes. Parasitology. 2018 Sep;145(10):1304-1310. doi: 10.1017/S0031182018000823. Epub 2018 May 28. PMID: 29806577; PMCID: PMC6137378.

[6]Gratton R, Tricarico PM, Guimaraes RL, Celsi F, Crovella S. Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line. Curr HIV Res. 2018;16(2):106-112. doi: 10.2174/1570162X16666180528100922. PMID: 29804534.

Lopinavir 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.95mL

1.59mL

0.80mL

15.90mL

3.18mL

1.59mL

Lopinavir 技术信息

CAS号192725-17-0
分子式C37H48N4O5
分子量 628.801
别名 ABT-378;A-157378.0;Koletra;Aluviran
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 250 mg/mL(397.58 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

30% PEG400+0.5% Tween80+5% propylene glycol+water 30 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。